Mittie Doyle Sells 679 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $20.00, for a total value of $13,580.00. Following the completion of the sale, the insider owned 51,776 shares in the company, valued at $1,035,520. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00.
• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $19.34 on Thursday. The firm’s fifty day moving average is $19.08 and its 200-day moving average is $16.89. Avalo Therapeutics, Inc. has a 52 week low of $8.73 and a 52 week high of $24.27. The firm has a market cap of $1.04 billion, a P/E ratio of -4.43 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, sell-side analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AVTX shares. Bank of America started coverage on Avalo Therapeutics in a research report on Friday, June 12th. They issued a “buy” rating and a $35.00 price objective for the company. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Citizens Jmp decreased their target price on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Wedbush lowered their target price on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Finally, Mizuho boosted their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.10.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares in the last quarter. Nantahala Capital Management LLC increased its position in Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after buying an additional 95,000 shares in the last quarter. Bank of America Corp DE increased its position in Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after buying an additional 400,898 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the 2nd quarter worth approximately $56,000. Finally, Vanguard Group Inc. raised its stake in Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.